Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography–Mass Spectrometry/Mass Spectrometry
Sign Up to like & getrecommendations! Published in 2024 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000001190
Abstract: Background: Ibrutinib and zanubrutinib are Bruton tyrosine kinase inhibitors used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Dihydroxydiol ibrutinib (DHI) is an active metabolite of the drug. A liquid chromatography–tandem… read more here.
Keywords: ibrutinib; ibrutinib zanubrutinib; mass spectrometry;
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19048
Abstract: e19048 Background: This study aimed to examine treatment adherence and healthcare resource utilization (HCRU) of BTKi treatment in mantle cell lymphoma (MCL). Methods: The Symphony Integrated Dataverse (IDV) was used to conduct a retrospective observational… read more here.
Keywords: treatment; adherence healthcare; adherence; ibrutinib zanubrutinib ... See more keywords